Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron vs placebo in men with overactive bladder on tamsulosin for BPH
2015-004036-36Phase 4Completed
- Sponsor
- Astellas Pharma
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in overactive bladder (OAB), benign prostatic hyperplasia (BPH) and urinary incontinence (UI) comparing Tamsulosin + Betmiga with Tamsulosin + placebo (2 arms). Primary endpoint: Change in mean number of micturitions per day. Started May 2016; status: completed.
02
Drugs
mirabegron
03
Conditions
overactive bladder (OAB)benign prostatic hyperplasia (BPH)urinary incontinence (UI)
Beyond the preview
Go deeper on 2015-004036-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004036-36.